Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 3
- Registration Number
- NCT00974662
- Locations
- 🇫🇷
Hopital Foch, Suresnes, France
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: WST 11 -mediated -VTP
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT00946881
- Locations
- 🇺🇸
NYU Urology Associates, New York, New York, United States
🇺🇸Washington University School of Medicine- Barnes-Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸UCLA - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Study of WST11 in Patients With Localized Prostate Cancer
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 42
- Registration Number
- NCT00707356
- Locations
- 🇫🇷
Hôpital Bocage-CHU, Dijon, France
🇬🇧Frimley Park Hospital NHS Trust, Frimley, United Kingdom
🇫🇷Institut Mutualiste Montsouris(IMM), Paris, France
© Copyright 2025. All Rights Reserved by MedPath